Search details
1.
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Nature
; 603(7903): 942-948, 2022 03.
Article
in English
| MEDLINE | ID: mdl-35322232
2.
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
N Engl J Med
; 388(3): 228-239, 2023 01 19.
Article
in English
| MEDLINE | ID: mdl-36652354
3.
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
N Engl J Med
; 384(13): 1191-1203, 2021 04 01.
Article
in English
| MEDLINE | ID: mdl-33789008
4.
International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape : Bertinoro Workshop, November 2022.
Gastric Cancer
; 2024 Apr 18.
Article
in English
| MEDLINE | ID: mdl-38634954
5.
Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415).
BMC Cancer
; 23(1): 561, 2023 Jun 19.
Article
in English
| MEDLINE | ID: mdl-37337155
6.
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).
BMC Cancer
; 23(1): 180, 2023 Feb 22.
Article
in English
| MEDLINE | ID: mdl-36814222
7.
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.
Eur Radiol
; 33(2): 1174-1184, 2023 Feb.
Article
in English
| MEDLINE | ID: mdl-35976398
8.
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus.
Future Oncol
; 19(11): 739-752, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-36919706
9.
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Int J Cancer
; 150(1): 112-123, 2022 01 01.
Article
in English
| MEDLINE | ID: mdl-34431518
10.
Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3).
Int J Cancer
; 150(8): 1341-1349, 2022 04 15.
Article
in English
| MEDLINE | ID: mdl-34807464
11.
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Lancet
; 398(10294): 27-40, 2021 07 03.
Article
in English
| MEDLINE | ID: mdl-34102137
12.
Predictive Value of Preoperative Endoscopic Ultrasound (EUS) After Neoadjuvant Chemotherapy in Locally Advanced Esophagogastric Cancer - Data From a Randomized German Phase II Trial.
Ultraschall Med
; 43(5): 514-521, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-35226933
13.
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
Int J Cancer
; 149(11): 1935-1943, 2021 12 01.
Article
in English
| MEDLINE | ID: mdl-34310714
14.
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group.
Br J Cancer
; 125(7): 911-919, 2021 09.
Article
in English
| MEDLINE | ID: mdl-34426663
15.
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Br J Cancer
; 124(3): 587-594, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33154570
16.
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
Future Oncol
; 17(10): 1155-1164, 2021 Apr.
Article
in English
| MEDLINE | ID: mdl-33263418
17.
A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.
Future Oncol
; 17(25): 3309-3319, 2021 Sep.
Article
in English
| MEDLINE | ID: mdl-33993741
18.
KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma.
Future Oncol
; 17(10): 1143-1153, 2021 Apr.
Article
in English
| MEDLINE | ID: mdl-33533655
19.
PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression.
Proc Natl Acad Sci U S A
; 115(17): E4061-E4070, 2018 04 24.
Article
in English
| MEDLINE | ID: mdl-29632181
20.
Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer.
J Hepatol
; 73(5): 1109-1117, 2020 11.
Article
in English
| MEDLINE | ID: mdl-32446715